Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer

Background: Anlotinib is a novel anti-angiogenesis drug. In non-small cell lung cancer (NSCLC), high body mass index (BMI) was not associated with worse survival in patients treated with bevacizumab compared with those with normal or low BMI. However, it remains unknown whether such an association s...

Full description

Bibliographic Details
Main Authors: Anning Xiong, Wei Nie, Lei Cheng, Hua Zhong, Tianqing Chu, Runbo Zhong, Jun Lu, Shuyuan Wang, Jianlin Xu, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Pharmacology
Subjects:
VEGFR-TKIs
body mass index
anti-angiogenesis
predictive biomarker
multi-targer drug
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.812555/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.812555/full

Similar Items